KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Prepaid Assets: 2013-2025

Historic Prepaid Assets for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $28.0 million.

  • Travere Therapeutics' Prepaid Assets rose 77.80% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 77.80%. This contributed to the annual value of $12.7 million for FY2024, which is 34.39% down from last year.
  • As of Q3 2025, Travere Therapeutics' Prepaid Assets stood at $28.0 million, which was up 62.86% from $17.2 million recorded in Q2 2025.
  • Travere Therapeutics' Prepaid Assets' 5-year high stood at $28.0 million during Q3 2025, with a 5-year trough of $6.5 million in Q1 2022.
  • Its 3-year average for Prepaid Assets is $16.0 million, with a median of $15.1 million in 2023.
  • In the last 5 years, Travere Therapeutics' Prepaid Assets spiked by 132.70% in 2023 and then crashed by 34.39% in 2024.
  • Travere Therapeutics' Prepaid Assets (Quarterly) stood at $6.7 million in 2021, then skyrocketed by 79.12% to $12.0 million in 2022, then soared by 60.68% to $19.3 million in 2023, then crashed by 34.39% to $12.7 million in 2024, then spiked by 77.80% to $28.0 million in 2025.
  • Its Prepaid Assets was $28.0 million in Q3 2025, compared to $17.2 million in Q2 2025 and $13.6 million in Q1 2025.